Publications by authors named "A Minello"
Background And Aims: Bulevirtide (BLV) 2 mg/day is EMA approved for treatment of compensated chronic hepatitis due to Delta virus (HDV) infection, however real-life data in large cohorts of patients with cirrhosis are lacking.
Methods: Consecutive HDV-infected patients with cirrhosis starting BLV 2 mg/day since September 2019 were included in a European retrospective multicenter real-life study (SAVE-D). Patient characteristics before and during BLV treatment were collected.
Article Synopsis
- Bulevirtide is a new antiviral therapy specifically designed to treat chronic hepatitis D, and researchers aimed to understand its effectiveness alone and in combination with pegylated-interferon (Peg-IFN).
- Mathematical modeling of data from 183 patients showed that bulevirtide effectively blocks cell infection by 90.3%, while Peg-IFN blocks viral production at 92.4%, leading to enhanced outcomes when combined.
- Results indicated that combining bulevirtide with Peg-IFN resulted in a higher rate of viral decline and a better chance of achieving a cure, suggesting the need for further randomized clinical trials to assess treatment effectiveness.
Background & Aims: In France, bulevirtide (BLV) became available in September 2019 through an early access program to treat patients with HDV. The aim of this analysis was to evaluate the efficacy and safety of BLV in patients with HIV and HDV coinfection.
Methods: Patients received BLV 2 mg ± pegylated interferon-α (pegIFNα) according to the physician's decision.
Transjugular intrahepatic portosystemic shunt (TIPS) has become essential in the treatment or prevention of portal hypertension-related complications. In the early 1990s, the primary indication was refractory bleeding. It is now proposed for the treatment of ascites for the prevention of bleeding and in patients with vascular diseases of the liver.
View Article and Find Full Text PDFBackground: In recent years, age at liver transplantation (LT) has markedly increased. In the context of organ shortage, we investigated the impact of recipient age on post-transplantation mortality.
Methods: All adult patients who received a first LT between 2007 and 2017 were included in this cross-sectional study.